Literature DB >> 1684365

A restriction fragment of the C2 gene is a unique marker for C2 deficiency and the uncommon C2 allele C2*B (a marker for type 1 diabetes).

S Simon1, Z Awdeh, R D Campbell, P Ronco, S J Brink, G S Eisenbarth, E J Yunis, C A Alper.   

Abstract

There are three common C2 protein alleles in caucasians, C2*C, C2*B, and C2*Q0, with allele frequencies of 0.96, 0.03, and 0.01, as well as Sst I RFLP variants of 2.75, 2.7, 2.65, 2.55, and 2.4 kb, with frequencies of 0.017, 0.533, 0.358, 0.017, and 0.075. Thus, C2*C is informatively split by the RFLP. Of 94 nonrandomly ascertained caucasian complotypes, 77 contained C2*C, four contained C2*Q0, and 13 had C2*B. None of the C2*C-containing complotypes carried the 2.75 kb Sst I fragment and all of the complotypes with C2*B or C2*Q0 carried it. All of the C2*Q0 alleles were associated with C4A*4, C4B*2 in the complotype S042 as previously reported. C2*B was usually (9/13) in the complotype SB42, occasionally (1/13 each) in SB45, SB41, SB(4,3)0, and SB31. Thus, the association of the C2 2.75-kb fragment was with C2*B and C2*Q0, not with C4A*4, C4B*2, or even C4A*4 alone. The complotype SC42 was associated with the 2.65-kb Sst I fragment in four of five instances and in a single example with the 2.7-kb fragment. C2*B and C2*Q0 possibly had a common evolutionary ancestor complotype which carried the 2.75-kb Sst I fragment, and BF*S, C4A*4, and C4B*2. C2*B (particularly as the haplotype HLA-Bw62, SB42, DR4) is associated with type 1 diabetes but C2*Q0 is protective.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1684365      PMCID: PMC295824          DOI: 10.1172/JCI115545

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  28 in total

1.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

2.  Allelic associations of multiple RFLPs of the gene encoding complement protein C2.

Authors:  Z B Zhu; J E Volanakis
Journal:  Am J Hum Genet       Date:  1990-05       Impact factor: 11.025

3.  Phenotyping of human complement component C4, a class-III HLA antigen.

Authors:  E Sim; S J Cross
Journal:  Biochem J       Date:  1986-11-01       Impact factor: 3.857

4.  Molecular mapping of the human major histocompatibility complex by pulsed-field gel electrophoresis.

Authors:  I Dunham; C A Sargent; J Trowsdale; R D Campbell
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

5.  DNA polymorphism of the C2 locus.

Authors:  D R Bentley; R D Campbell; S J Cross
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

6.  Statement on the nomenclature of human C4 allotypes.

Authors:  G Mauff; C A Alper; Z Awdeh; J R Batchelor; J Bertrams; G Bruun-Petersen; R L Dawkins; P Démant; J Edwards; H Grosse-Wilde; G Hauptmann; P Klouda; L Lamm; E Mollenhauer; C Nerl; B Olaisen; G O'Neill; C Rittner; M H Roos; V Skanes; P Teisberg; L Wells
Journal:  Immunobiology       Date:  1983-03       Impact factor: 3.144

7.  A molecular map of the human major histocompatibility complex class III region linking complement genes C4, C2 and factor B.

Authors:  M C Carroll; R D Campbell; D R Bentley; R R Porter
Journal:  Nature       Date:  1984 Jan 19-25       Impact factor: 49.962

8.  Major histocompatibility complex haplotype studies in Ashkenazi Jewish patients with pemphigus vulgaris.

Authors:  A R Ahmed; E J Yunis; K Khatri; R Wagner; G Notani; Z Awdeh; C A Alper
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

9.  The molecular basis for genetic deficiency of the second component of human complement.

Authors:  F S Cole; A S Whitehead; H S Auerbach; T Lint; H J Zeitz; P Kilbridge; H R Colten
Journal:  N Engl J Med       Date:  1985-07-04       Impact factor: 91.245

10.  C2 and factor B: structure and genetics.

Authors:  D R Bentley; R D Campbell
Journal:  Biochem Soc Symp       Date:  1986
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.